Innovation in Gynecologic Cancer Surgery

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gynecologic Oncology".

Deadline for manuscript submissions: 31 May 2026 | Viewed by 1212

Special Issue Editor


E-Mail Website
Guest Editor
Clinical Research, Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL, USA
Interests: clinical and surgical outcomes; gynecologic oncology; robotic surgery in gynecology; hemostasis and thrombosis; hemato-oncology; lifestyle medicine

Special Issue Information

Dear Colleagues,

Hysterectomy remains a cornerstone in the surgical management of gynecologic malignancies, including cervical, endometrial, and ovarian cancers. Over the past decades, advances in surgical techniques, imaging, and oncologic understanding have reshaped the role and extent of hysterectomy in cancer care. Minimally invasive approaches, nerve-sparing techniques, and fertility-preserving options are now being increasingly considered, tailored to the disease stage and patient profile.

This Special Issue aims to explore the current standards and emerging innovations in hysterectomy for gynecologic cancers. We welcome original research, systematic reviews, and expert perspectives that examine surgical approaches, decision-making algorithms, outcomes, complications, and cost-effectiveness. Special attention will be given to evolving topics such as robotic-assisted surgery, individualized surgical planning, quality-of-life outcomes, survivorship, and integration of hysterectomy within multimodal cancer treatment.

By bringing together diverse contributions from surgical oncologists, gynecologists, and innovative researchers, this issue seeks to provide a comprehensive overview of where we stand today and where the field is headed in the surgical treatment of gynecologic cancers.

Prof. Dr. Sarfraz Ahmad
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hysterectomy
  • gynecologic cancers
  • surgical oncology
  • minimally invasive surgery
  • fertility preservation
  • survivorship
  • cost-effectiveness

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 881 KB  
Article
Recurrence Patterns After Complete Cytoreduction for Advanced Ovarian Cancer: Robotic Versus Open Surgery
by Yossi Tzur, Yoav Brezinov, Tomer Bar-Noy, Amber Yasmeen, Melica Nourmoussavi Brodeur, Shannon Salvador, Walter H. Gotlieb and Susie Lau
Curr. Oncol. 2026, 33(2), 71; https://doi.org/10.3390/curroncol33020071 - 26 Jan 2026
Viewed by 697
Abstract
Background: Complete cytoreduction remains the primary surgical objective in advanced ovarian cancer and concerns persist that robotic surgery may result in distinct recurrence patterns and worse oncologic outcomes due to technical limitations, such as the use of pneumoperitoneum, the restricted visualization, and the [...] Read more.
Background: Complete cytoreduction remains the primary surgical objective in advanced ovarian cancer and concerns persist that robotic surgery may result in distinct recurrence patterns and worse oncologic outcomes due to technical limitations, such as the use of pneumoperitoneum, the restricted visualization, and the lack of tactile evaluation. Methods: We retrospectively identified 125 consecutive patients with advanced epithelial ovarian cancer who attained the best outcome surgery can achieve, and compared the outcome of these patients based on whether complete cytoreduction was achieved by laparotomy or robotic surgery. The primary objective was to compare recurrence patterns and secondary analyses assessed perioperative, postoperative, and survival outcomes. Results: Among 125 patients who had complete cytoreduction (78 robotic; 47 open), baseline characteristics were largely comparable, except for higher rates of interval cytoreduction (84.6% vs. 61.7%, p < 0.01) and more PARP inhibitor use (19.2% vs. 6.4%, p = 0.048) in the robotic group. Recurrence patterns did not differ. Operative and postoperative outcomes were likewise comparable. Median disease-free and overall survival were longer in the robotic group. Conclusions: Among patients achieving complete cytoreduction, recurrence patterns and oncologic outcomes were comparable between robotic and open surgery, suggesting that the route of attaining complete cytoreduction did not influence the outcome. Full article
(This article belongs to the Special Issue Innovation in Gynecologic Cancer Surgery)
Show Figures

Graphical abstract

Back to TopTop